Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights GlobeNewswire - Mon Mar 23, 3:05PM CDT

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...

STRO : 24.43 (-1.93%)
Biotech research by Gorodenkoff via Shutterstock
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. Barchart - Mon Mar 2, 2:28PM CST

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 53.16 (-2.83%)
STRO : 24.43 (-1.93%)
LZAGY : 61.2400 (-0.46%)
Sutro Biopharma to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 7:30AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces Participation at the 16th World ADC London Summit GlobeNewswire - Mon Feb 23, 7:30AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering GlobeNewswire - Tue Feb 10, 6:00AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 7, 3:05PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire - Wed Dec 17, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Dec 16, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors GlobeNewswire - Wed Dec 3, 2025

– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces 1-for-10 Reverse Stock Split GlobeNewswire - Mon Dec 1, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)

Barchart Exclusives

Only 1 of These Top 2 REITs Is Built to Pay You for Generations Barchart - Fri Mar 27, 6:00PM CDT
VICI or Realty Income? One offers higher yield and growth, while the other may benefit more when rate cuts arrive. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.